This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | MicrobiomeTrials
← Back to trials NCT02952508
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2017-07-26Est. Completion: 2026-06-22
Enrollment target: 120 participantsLocations Cellectar Biosciences site, Los Angeles, California, United States Cellectar Biosciences site, Redlands, California, United States Cellectar Biosciences site, Washington D.C., District of Columbia, United States Cellectar Biosciences site, Jacksonville, Florida, United States Cellectar Biosciences site, Miami, Florida, United States Cellectar Biosciences site, Tampa, Florida, United States Cellectar Biosciences, Atlanta, Georgia, United States Cellectar Biosciences site, Maywood, Illinois, United States Cellectar Biosciences site, Warrenville, Illinois, United States Cellectar Biosciences site, Westwood, Kansas, United States Cellectar Biosciences site, New Orleans, Louisiana, United States Cellectar Biosciences site, Baltimore, Maryland, United States Cellectar Biosciences, Bethesda, Maryland, United States Cellectar Biosciences site, Boston, Massachusetts, United States Cellectar Biosciences, North Bergen, New Jersey, United States Cellectar Biosciences site, Buffalo, New York, United States Other microbiome trials you might be interested in Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Mantle Cell Lymphoma (MCL) Marginal Zone Lymphoma (MZL) Waldenstrom Macroglobulinemia (WM) Primary Central Nervous System Lymphoma (PCNSL) Secondary Central Nervous System Lymphoma (SCNSL)
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activ…
Duarte, United States Est. completion Jan 2027
Cellectar Biosciences site, New York, New York, United States
Cellectar Biosciences site, Rochester, New York, United States
Cellectar Biosciences site, Durham, North Carolina, United States
Cellectar Biosciences, Canton, Ohio, United States
Cellectar Biosciences site, Cincinnati, Ohio, United States
Cellectar Biosciences Site, Charleston, South Carolina, United States
Cellectar Biosciences, Greenville, South Carolina, United States
Cellectar Biosciences site, Knoxville, Tennessee, United States
Cellectar Biosciences site, Dallas, Texas, United States
Cellectar Biosciences site, Dallas, Texas, United States
Cellectar Biosciences site, Houston, Texas, United States
Cellectar Biosciences site, Seattle, Washington, United States
Cellectar Biosciences site, Madison, Wisconsin, United States
Cellectar Biosciences site, Concord, New South Wales, Australia
Cellectar Biosciences, Adelaide, South Australia, Australia
Cellectar Biosciences, Salvador, Estado de Bahia, Brazil
Cellectar Biosciences, Curitiba, Paraná, Brazil
Cellectar Biosciences, Porto Alegre, RioGrande Do Sul, Brazil
Cellectar Biosciences, Blumenau, Santa Catarina, Brazil
Cellectar Biosciences Site, Hradec Králové, Czechia
Cellectar Biosciences, Helsinki, Finland
Cellectar Biosciences, Pessac, France
Cellectar Biosciences, Poitiers, France
Cellectar Biosciences site, Athens, Greece
Cellectar Biosciences Site, Rio, Greece
Cellectar Biosciences Site, Jerusalem, Israel
Cellectar Biosciences, Barcelona, Spain
Cellectar Biosciences site, Barcelona, Spain
Cellectar Biosciences, Madrid, Spain
Cellectar Biosciences, Madrid, Spain
Cellectar Biosciences, Salamanca, Spain
Cellectar Biosciences site, Zaragoza, Spain
Cellectar Biosciences, Ankara, Turkey (Türkiye)
Cellectar Biosciences, Bornova, Turkey (Türkiye)
Cellectar Biosciences, Istanbul, Turkey (Türkiye)
Cellectar Biosciences site, London, United Kingdom Recruiting
Waldenstrom Macroglobulinemia Chronic Lymphocytic Leukemia Hodgkin Disease NonHodgkin Lymphoma Mixed Lymphoproliferative Disease
Background:
* Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of r…
Hematologic Cancer
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood …
Tempe, United States Est. completion Mar 2031